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Abstract— Available mathematical models of tumor growth and 
the effect of anticancer treatments in animals are still of limited 
practical use within the drug industry because of complex and 
contradictory aspects. A simple and effective model would 
facilitate the preclinical development of oncology drugs owing to 
prediction capabilities. Another challenge of this field is to 
estimate the model parameters according to laboratory 
experimental data. Simplicity of mathematical models often causes 
a major impediment in fitting the models to experimental data. In 
this paper, a minimal Pharmacokinetic-Pharmacodynamic (PK-
PD) model is studied to analyze the effects of antitumor drugs 
using empirical data obtained from the experimentations on 5 
groups of laboratory mice: one group untreated and 4 groups 
treated with four different antitumor drugs which are intravenously 
administered. Tumor growth and process of cell death are here 
modeled by three differential equations obtained from a 
compartmental model. The related compartmental model is then 
applied to experimental data supposing an exponential decaying 
model for drug concentration. Using Genetic algorithms, the 
parameters of model have been optimally estimated. According to 
simulations, the proposed model copes with the interpretation of 
contradictory effects of CpG drug. Besides, the parameters of 
immunological system are uniquely obtained in the presence of 
different anticancer drugs. Proposed model parameters may be 
used in the prediction of an eventual treatment of mixing profile.   
Keywords: drug, tumor growth, model; mice, genetic 
algorithm. 
I.  Introduction  
To understand and predict the pharmacological behavior 
of anticancer drugs, it is crucial to quantify the time course 
of pharmacodynamic responses in relation to the plasma 
concentration. The response of anticancer drugs is delayed 
relative to the time course of drug exposure. 
A fundamental step of the preclinical development of 
oncology drugs is the in vivo evaluation of the antitumor 
effect. For this purpose, a series of experiments are 
performed, in which tumor cells from immortalized cell lines 
are inoculated into athymic mice. Tumor volumes are 
measured at different times throughout the experiment in all 
of the animals, treated either with a vehicle (control) or with 
an active drug. The effect of the active molecule is then 
measured by comparing the average tumor weights in treated 
and control animals at the end of the experiment, or by 
recording the animals surviving their disease [1-3]. This 
approach can be used to select the most potent candidate 
within a series using the same dosing regimen, or the most 
appropriate dosing regimen among those tested for a specific 
compound. However, in this way, the time course of the 
tumor growth is often neglected, so that only partial use of 
the information available from the experiment is made. 
Empirical models use mathematical equations (e.g., 
sigmoid functions, such as logistic, Verhulst, Gompertz, and 
von Bertalanffy [4,5]) to describe the tumor growth process, 
without an in-depth mechanistic description of the 
underlying physiological processes. In this context, the effect 
of a drug can be evaluated only in terms of changes of the 
parameter values describing the tumor growth. These 
changes depend on the dose level as well as the 
administration schedule, so that those approaches can be 
applied only retrospectively and not as predictive tools when 
used outside the tested regimens. 
Functional models, conversely, are based on mechanistic, 
physiology-based hypotheses. They suppose a set of 
assumptions about the tumor growth, including cell-cycle 
kinetics and biochemical processes, such as those related to 
anti-angiogenetic and/or immunological responses [5,6]. 
Such models usually represent the cell population in its 
heterogeneity, splitting it into at least two subpopulations: 
the proliferating and the quiescent cells. More complex 
models describe the cell population as age-structured and 
take into account subpopulations related to specific phases of 
the cell cycle. These models have a much larger number of 
parameters compared with the empirical ones. Their 
development is time consuming and a number of quantitative 
observations (e.g., flow cytometry analyses, biochemical and 
immunological marker measurements, and so forth) are 
required to avoid the identifiability problems due to the over-
parameterization [7]. The situation becomes even more 
complex when the effect of the treatment with an anticancer 
drug is considered [8-11], also because of the incomplete 
knowledge of the mode of action in vivo. As a consequence, 
these models are rarely used in industrial drug research. 
In conclusion, despite the existence of several tumor 
growth models, a practical tool that supports oncology drug 
development is still missing. In this respect, the only metrics 
of success are its application to the experimental data and the 
savings of experiments, time, costs, resources, and animal 
requirements. In this article, the described model is an 
effective compromise between empirical and mechanism-
based approaches. It relies on a few identifiable and 
biologically relevant parameters, the estimation of which 
requires only the data typically available in the preclinical 
setting: the pharmacokinetics of the anticancer agents and the 
tumor growth curves in vivo.  According to the large 
uncertainty about the parameter space, the model parameters 
have been estimated using Genetic algorithm in this paper. 
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II. PK-PD Model of Tumor Growth 
A. Introduction 
A Pharmacokinetic-Pharmacodynamic (PK-PD) model 
would greatly improve the preclinical development of 
oncology drugs linking the administration regimen of an 
agent to tumor growth dynamics. To achieve this property, it 
is firstly necessary to have a mathematical model governing 
on the progression of disease in the absence of any treating 
agent [12]. 
Empirical models can use mathematical differential 
equations to describe the tumor growth curve, without an in-
depth mechanistic description of the underlying 
physiological processes. However, the modeling equations 
should already be extracted from the physio-pathological 
phenomena and reactions. In first dilemma, the effect of a 
drug can be evaluated only in terms of changes of the 
parameter values describing the tumor growth. These 
changes depend mostly on the dose level and the 
administration schedule. So, the related approaches can be 
applied only retrospectively and may not be used as 
predictive tools out of the tested regimens. The predicting 
capability relies on the basic PK-PD model comprising the 
relevant chemical reaction chains [13]. 
The availability of mathematical models being able to 
predict the dynamics of tumor growth as a function of the 
drug concentration would result in several advantages such 
as saving time and cost of experimentation and validation of 
immunotherapeutic theories. The mathematical modeling of 
tumor growth dynamics has been under extensive 
investigations [14]. All proposed models generally involve a 
dozen of parameters that can be hardly identified from the 
experimental data. In this paper, a PK-PD model is used with 
four parameters [15,16]. The parameters of the 
pharmacodynamic model are related to the growth 
characteristics of tumor, drug potency, and the kinetics of the 
tumor cell death. The model parameters are then optimally 
estimated according to the experimental data applying 
genetic algorithms as optimization tools. Finally, the model 
can be used to describe or predict the tumor growth rate 
considering different vaccination profiles. Also, it may be 
used to propose new mixing profiles of vaccination as a 
prospective drug. 
This paper has been organized as follows. The next 
section describes a PK-PD model for tumor growth. In the 
third section, the experimentation procedures have been 
explained. Also, the result simulation results are discussed. 
Finally, the results are summarized in the conclusion section.  
B. PK-PD Model  
In untreated mice, experimental data demonstrate that 
tumor growth follows two distinctive and different phases: 
first, an initial phase with exponential growth, secondly a 
linear growth phase and a smooth transition between two 
phases. In treated animals, the tumor growth rate is 
proportionally decreased in terms of both drug concentration 
and the concentration of proliferating tumor cells. Anticancer 
treatment influences basic growth dynamics of tumor so that 
proliferating cells become non-proliferating with a rate 
depending on the drug concentration in plasma. Invoking 
immunological principles, the tumor growth in the presence 
of antitumor drug may be modeled by a compartment model 
as shown in Fig.1. [17]: 
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In this model, all tumor cells are assumed to be 
proliferating. The model assumes that the anticancer 
treatment makes some cells nonproliferating as well (Fig.1), 
eventually bringing them to death. For a given time t, x1(t) 
indicates the portion of proliferating cells within the total 
tumor weight w(t) and c(t) indicates the plasma 
concentration of the anticancer agent respectively. x1(t) 
represents the portion of w(t) that is actually proliferating. 
The model assumes that the drug elicits its effect decreasing 
the tumor growth rate by a factor proportional to )().( 1 txtc   
through the constant parameter k2, which is, thus, an index of 
drug efficacy [17]. 
It is assumed that the cells affected by drug action stop 
proliferating and pass through n different stages (namely 
x2,…, xn), characterized by progressive degrees of damage, 
and, eventually, they die. The dynamics by which the cells 
proceed through progressive degrees of damage is modulated 
via a rate constant k1 that can be interpreted in terms of the 
kinetics of cell death. 
In practice, the drug absorption function can be replaced 
as following [17]: 
( )( ) t tβC t e eα βγβ α − −= −−    (5)                    
That C(t), β , α  and γ  stand for the mean plasma 
concentration of drug, absorption and elimination rates and 
the volume of distribution respectively. 
 
Figure 1.  Scheme of PK-PD  model of cell death. k1 : first order rate 
constant of transit; k2 :measure of drug potency; C(t): the plasma 
concentration of anticancer agent. 
In the experimental study of this paper, the parameters 
λ0, λ1, k1, k2( )  are supposed to be constant through different 
vaccination profiles (model parameters). The model 
parameters are to be optimally estimated by genetic 
algorithms invoking the experimental data. Contradictory 
effects of different vaccins (CpG versus Listeria for 
example) renders the optimization problem tough. 
III. Experimentations and Simulation Results 
In the experiments, tumor cells were subcutaneously 
inoculated to mice. With a palpable tumor after one week, 
they are randomly divided into 5 groups: one untreated and 4 
others treated by 4 different drugs of Lps, CpG, Tumor 
Lysate and Listeria monocytogenes. Each drug is 
administered in 3 classes: once, twice and triple injection on 
7th, 10th and 13th day respectively. Then, the tumor size is 
tracked every two days for all groups. The parameters of PK-
PD model are estimated invoking experimentation data. 
Using experimentation data, the PK-PD model is simulated 
for different groups of mice. Genetic algorithm toolbox of 
Matlab is used to optimize the model parameters so that the 
total error tends to minimum. Simulations took about 30 
minutes for each run of optimization toolbox (P4 dual core, 
RAM 4GB). In the simulations, four stages of damage (n=4) 
for cells are considered and the model is a four compartment 
model. 
Once  the optimization toolbox with seven parameters to 
be estimated λ0, λ1, k1, k2,α, β,γ( )  is executed, a limit range 
for variation of drug parameters is obtained. The drug 
parameters for those mice in CpG group and Listeria group 
are reported in table I. 
TABLE I: Drug parameters of CpG and Listeria for distribution in plasma. 
 α  β  γ  
CpG 0.252 0.651 1.53 
Listeria 0.151 0.21 0.82 
 
The drug concentration for CpG group with triple 
injection on 7th, 10th and 13th day is shown in Fig. 2. It can be 
seen that after first, second and third injections, the plasma 
concentration of the drug goes up and eventually decreases 
exponentially being consistent with the physiology. 
 
Figure 2.  Mean plasma concentration of CpG with triple injections. 
 
Figure 3.  Mean plasma concentration of Listeria with double injections. 
The drug concentration for Listeria group with twice 
injection on 7th and 10th days is shown in Fig. 3. 
Now, the optimization toolbox for each group of mice 
with different drug administration is invoked and 
accordingly the model parameters for each group is obtained 
(see table I). It can be seen from estimated parameters for 
each group that the range of their variation is the same. In the 
next stage, the mean estimated value for each estimated 
parameter is used. It may be seen from the results that the 
result parameters have been estimated with a good accuracy. 
The model parameters are finally obtained as shown in table 
III invoking different vaccination profiles and agents. 
Then, using the proposed dynamic parameters (Table III), 
the optimization toolbox is run invoking each group of 
experimentation mice and considering the related 
vaccination C(t). Simulation results have been shown  in 
Figure 4.  
TABLE II: Proposed Model parameters using experimental trials for 
different vaccines types. 
 
0λ  1λ  1k  2k  
Lps 1.019 5.56 0.1038 0.199 
CpG 1.0136 6.5 0.3999 0.1118 
Lysate 0.8 5.5 0.1969 0.2 
Listeria  1.158 6.13 0.148 0.63 






























































































Figure 4.  Average tumor growth: empirical (in blue) and simulated (in red) values. The curves are associated with the different vaccination trials of:                                       
(a) Listeria group (top left); (b) Lps group (top right); (c) CpG group (bottom left) and (d) Lysate group 9bottom right). 
TABLE III: Optimized  model parameters for fifferent vaccination groups 
0λ  1λ  1k  2k  
0.9995 5.9225 0.2121 0.285 
 
As it may be seen in Figure 4, the model curves can 
properly follow up the empirical data in spite of 
contradictory behavior of CpG agent versus other 
vaccination agents. 
In the next step of research, this model will be used to 
predict the performance of immunology system and the 
tumor size using different profiles of vaccination.  
IV. Conclusion 
In this paper, a novel PK-PD model was presented for 
predicting and describing the tumor growth and the effect of 
anticancer agents in animal models. The pharmacodynamic 
part of the model was based on four physiological 
parameters. These parameters are identifiable without 
additional efforts, using the typical experiments performed in 
nude mice as part of the drug research and development 
process. Three parameters (w0, 0λ , and 1λ ) describe the 
features of the tumor kinetics in control animals, 
characterized by an exponential growth followed by a linear 
growth. Despite contradictory behavior of experimented 
drugs, the optimization process resulted in a series of 
optimum parameters for model. It exhibits the compatibility 
of the PK-PD model with experimentations data. Thus, the 
mentioned PK-PD model may be used to predict the tumor 
growth in the presence of different dosage of drugs. Besides, 
the model may be used to predict the tumor growth invoking 
combinational vaccinations. 
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